Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmaCorp RxTSXV:PCRX -1.00%35 EV-to-EBITDA is 483.80 as of Aug. 13, 2026, which is 1063% above its 10-year median of 41.60. GuruFocus rates TSXV:PCRX with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 512 Healthcare Providers & Services companies, PharmaCorp Rx ranks worse than 99.02% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PharmaCorp Rx's enterprise value is C$78.86 Mil.
PharmaCorp Rx's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was C$0.16 Mil. Therefore, PharmaCorp Rx's EV-to-EBITDA for today is 483.80.
The historical rank and industry rank for PharmaCorp Rx's EV-to-EBITDA or its related term are showing as below:
TSXV:PCRX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -725.61 Med: 41.6 Max: 489.83
Current: 483.8
During the past 5 years, the highest EV-to-EBITDA of PharmaCorp Rx was 489.83. The lowest was -725.61. And the median was 41.60.
TSXV:PCRX's EV-to-EBITDA is ranked worse than 99.02% of 512
companies
in the Healthcare Providers & Services industry
Industry Median: 10.835
vs TSXV:PCRX: 483.80
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PharmaCorp Rx's PE Ratio (TTM) for today is calculated as:
PharmaCorp Rx's share price for today is C$0.495.
PharmaCorp Rx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for PharmaCorp Rx's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, PharmaCorp Rx's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCorp Rx EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PharmaCorp Rx's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PharmaCorp Rx's EV-to-EBITDA falls into.
PharmaCorp Rx's current Enterprise Value is C$78.86 Mil.
PharmaCorp Rx's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCorp Rx (TSXV:PCRX) has a EV-to-EBITDA of 483.80 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PharmaCorp Rx. This is 1063% above median its historical median of 41.60. According to the industry distribution chart, PharmaCorp Rx ranks #507 out of 512 companies in the Healthcare Providers & Services industry, placing it in the top 99%.
Is PharmaCorp Rx's EV-to-EBITDA too high?
PharmaCorp Rx's current EV-to-EBITDA of 483.80 is 1063% above median its 10-year median of 41.60. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.84. PharmaCorp Rx's value of 483.80 is 4365.2% above this industry median. Based on the distribution chart, PharmaCorp Rx ranks #507 out of 512 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, PharmaCorp Rx has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCorp Rx's EV-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, PharmaCorp Rx ranks #507 out of 512 companies for EV-to-EBITDA. This places PharmaCorp Rx in the lower half of its industry. The industry median EV-to-EBITDA is 10.84. PharmaCorp Rx's value of 483.80 is 4365.2% above this benchmark. While the company's 10-year median is 41.60 vs. the industry median of 10.84, PharmaCorp Rx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.84, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaCorp Rx's current EV-to-EBITDA of 483.80 is 4365.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PharmaCorp Rx. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCorp Rx's current EV-to-EBITDA is 483.80, which is 1063% above median its own 10-year median of 41.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCorp Rx stock overvalued right now?
PharmaCorp Rx (TSXV:PCRX) has a current EV-to-EBITDA of 483.80. The current EV-to-EBITDA is 483.80, which is 1063% above median its 10-year median of 41.60 and 4365.2% above the Healthcare Providers & Services industry median of 10.84. PharmaCorp Rx's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PharmaCorp Rx (TSXV:PCRX), the current EV-to-EBITDA is 483.80 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCorp Rx Inc operates three PharmaChoice bannered pharmacies in Canada and will continue to acquire PharmaChoice Canada-branded pharmacies as it come to market in conjunction with its strategic alliance agreement with PharmaChoice Canada. The company will also acquire independently owned non-PharmaChoice Canada-bannered pharmacies in Canada, and thereafter, continue to operate such acquired pharmacies under a PharmaChoice Canada banner.
35GF Score
Get the complete analysis for TSXV:PCRX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:PCRX has been successfully added to your 
